SoftBank, the Japanese tech giant, has announced a joint venture (JV) with Tempus, a Chicago-based healthcare technology company, to establish a foothold in the AI-powered healthcare sector in Japan. This venture, named SB Tempus, aims to leverage artificial intelligence (AI) to analyze personal medical data to provide personalized treatment recommendations.
ソフトバンクグループ、Tempusとともに医療データとAIの活用により日本の医療のさらなる進歩に貢献するジョイントベンチャー「SB TEMPUS」を設立https://t.co/jtSgTfW4pi#ソフトバンクグループ #SoftBankGroup
— SoftBank Group Corp. (@SoftBank_Group) June 27, 2024
The news comes on the heels of SoftBank’s $200 million investment in Tempus earlier this year, just before Tempus’s initial public offering (IPO). This partnership signifies a strategic move by SoftBank to expand its presence in AI, an area of continued focus for the company, while Tempus gains access to the vast Japanese healthcare market.
SB Tempus plans to initially focus on oncology, considering cancer remains the leading cause of death in Japan. This focus aligns with a personal motivation for SoftBank founder Masayoshi Son, who lost his father to cancer last year.
The venture will utilize Tempus’s expertise in AI-powered healthcare data analysis, which involves interpreting medical tests and aiding healthcare professionals in providing more precise treatments. By leveraging SoftBank’s resources and the power of the Azure cloud platform from Microsoft (with whom SoftBank also has a partnership), SB Tempus will have the necessary infrastructure to analyze vast amounts of medical data efficiently.
This AI-powered approach to healthcare holds immense promise. By analyzing patient data, SB Tempus can potentially identify patterns and trends that might be missed by traditional methods, leading to earlier diagnoses, more effective treatment plans, and improved patient outcomes. Additionally, the scalability of AI allows for the potential personalization of medicine, tailoring treatments to individual patients based on their unique medical history.
